DOCSLIB.ORG

Drug Testing - AHS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Testing - AHS What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background • The qualitative drug test is often referred to as the “drug screen” - a misnomer • Testing performed using: – Immunoassay – GC/MS or LC/MS/MS confirmation techniques 2 1 Immunoassay – Initial Testing • Antigen-Antibody reactions • Refers to instrument based and non-instrument based techniques • Designed to detect a broad class of drugs • Cross-reactivity (the ability to detect a drug) dependent on reagent chemistry and devices used • Limited in scope (i.e. limited number of assays available) • Prone to false negatives and false positives 3 Confirmation Testing • Uses GC/MS or LC/MS/MS techniques • Confirms immunoassay result or initial testing for drugs in which no immunoassay available. • More resource driven than immunoassay • Provides specificity that cannot be achieved with immunoassay 4 2 Amphetamines (CEDIA) • Designed to detect methamphetamine, amphetamine and MDMA (same or different assays) • Will potentially detect other amphetamine like drugs PMMA/PMA pseudoephedrine/ephedrine phentermine phenylpropanolamine mephentermine • Will detect non-amphetamine like drugs bupropion trifluoromethylphenylpiperazine (TFMPP) trazodone m-CPP (trazadone metabolite/BZP analog) ranitidine phenelzine breakdown fenofibrate 5 Cocaine Metabolite (KIMS) • Tends to be specific for cocaine metabolite (benzoylecgonine) • Cocaine can be used in hospital type procedures – Eye surgery – Nasal surgery • Cutting Agents – levamisole, diltiazem, hydroxyzine, phenacetin, benzocaine 6 3 Cocaine Cut in Alberta* 40.0% 34.8% 35.0% 33.3% 28.4% 30.0% 27.4% 24.1% Levamisole 25.0% Benzocaine 20.0% 15.5% Phenacetin 15.0% 9.8% Diltiazem 10.0% 6.9% 5.0% 3.0% 851 819 90 966 448 201934 262 646 0.0% Apr/09 ‐ Mar/10 Apr/10 ‐ Mar/11 Apr/11 ‐ Mar/12 *Data Courtesy Controlled Substances and Tobacco Directorate, Health Canada 7 Cocaine Pharmaceutical Cutting Agents UAH Percent of Cocaine Confirmed Specimens Containing Cutting Agents 80.0% 69.5% 70.0% 63.0% 60.0% 58.6% 50.0% 2010 40.0% 2011 2012 30.0% 25.0% 20.0% 18.3% 10.0% 4.0% 5.0% 1.5% 1.4% 0.0% Levamisole Phenacetin Diltiazem 8 4 Opiates (KIMS) • Designed to pick up morphine and codeine • Will detect other opioids but not as well – hydrocodone – hydromorphone • Does not detect: – methadone/methadone metabolite (specific immunoassay) – buprenorphine (detected using LC/MS/MS) • Detects oxycodone poorly (specific immunoassay) • Ofloxacin and rifampin can cause a false positive 9 Benzodiazepines (KIMS) • Tends to be fairly specific for benzodiazepines • Some benzodiazepines more detectable than others • Metabolite cross-reactivity can be poor • Oxaprozin (Daypro) can cause a false positive • Cross-reactivity table 10 5 Generic Name Trade Name 300 ng/mL Equivalent % Cross-Reactivity Clobazam 382 79 Chlordiazepoxide Librium 486 62 Desmethylchlordiazepoxide 517 58 Clonazepam Klonopin 445 67 7-aminoclonazepam 489 61 Flunitrazepam Rohypnol 424 71 7-aminoflunitrazepam 333 90 desmethylflunitrazepam 395 76 3-hydroxyflunitrazepam 584 51 Flurazepam Dalmane 490 61 Hydroxyethylflurazepam 347 87 didesethylflurazepam 423 71 Desalkylflurazepam 323 93 Lorazepam Ativan 487 62 Lorazepam glucuronide >20,000 1.1 Midazolam Versed 467 64 -hydroxymidazolam 431 70 Temazepam Restoril 409 73 Temazepam Glucuronide >20.000 1.0 Triazolam Halcion 352 85 -hydroxytriazolam 377 80 4-hydroxytriazolam 385 78 11 Marijuana Metabolite • Designed to detect the marijuana metabolite - 11-nor- 9-tetrahydrocannabinol-9-carboxylic acid but will detect other metabolites • Historically assay was quite robust • New techniques saw emergence of false positives: – pantoprazole / Pantoloc (for acid-reflux) and POCT devices – efavirenz / Sustiva (anti-viral) and CEDIA chemistry • Passive exposure • Baby wash products vs metabolites normally occurring in neonates 12 6 GC/MS or LC/MS/MS Confirmation Testing RECEIVE URINE • More resource driven than the immunoassay SAMPLE PREPARATION - EXTRACTION GC/MS (2 mL to 10 uL) • Gives a fingerprint of drug LC/MS/MS (1 mL to 250 uL) based on retention time and fragmentation pattern INJECTION ON GC/MS or LC/MS/MS • Identify specific compounds SEPARATION in GC or LC (Retention Time) • Considered confirmation tests FRAGMENTATION in MS (Library Match/SIM or MRM) 13 General Retention Times • Amphetamines up to 4 days • MDMA (Ecstasy) up to 4 days • Marijuana Metabolite up to 30 days (chronic vs occasional) • Cocaine metabolite up to 4 days • Opiates up to 3 days • Heroin Metabolite less than 1 day • Barbiturates days to weeks • Benzodiazepines days to weeks • Methadone up to 3 days • Alcohol less than 1 day 14 7 The STAT Drug Test • Qualitative toxicology testing is rarely of any value in emergent situations for the acute management of patients for several reasons: – It does not confirm or rule out significant poisoning. – It almost never provides information that leads to a meaningful change in acute medical management. – Countless drugs contribute to common clinical symptoms seen in an emergency department that are not tested for/detectable by immunoassay screening tests. – The testing is not specific (i.e. there are multiple false positives, which then require explanation and perhaps needless investigations). – A positive test does not mean that this is what is contributing to the patient's symptoms. • NOT diagnostic – cannot be used to diagnose poisoning 15 Qualitative Urine Drug Testing - AHS • Cannot be used as a measure of impairment • Not for employment related purposes • Not for insurance purposes • Not for drug facilitated assault • Not for accident investigation/impaired driving • Not for apprehending children under child and family services authorities • Use for the CLINICAL management of patients – determining compliance challenging 16 8 Contact Information - Toxicologists • Dr. Penny Colbourne 780-407-4729 • Dr. Don LeGatt 780-407-8444 • For acute management of the poisoned patient contact PADIS 1-800-332-1414 17 9.
Load more

Recommended publications
  • <I>Efavirenz</I>, New Therapeutic Agents for AIDS
    CONFERENCE REPORTS 295 CHIMIA 1999. 53. NO.6 CONFERENCE REPORTS Chimia 53 (1999) 295-304 © Neue Schweizerische Chemische Gesellschaft ISSN 0009-4293 Second Swiss/German Meeting on Medicinal Chemistry Fruhjahrsversammlung 1999 der Neuen Schweizerischen Chemischen Gesellschaft (NSCG) 22./23. Marz 1999, Basel Vier Mini-Symposia uber Virologie, Multidrug Resistance, Immunologie und Gene Therapie Organisiert von der Sektion Medizinische Ghemie der NSGG, der Fachgruppe fUr Medizinische Chemie der GDGh und der Basler Chemischen Gesellschatt mit Unterstutzung der Pharmazeutischen Industrie. Report by the Research Team of G. Folkers' 'Correspondence: Prof. Dr. G. Folkers Department of Pharmacy Winterthurerstrasse 190 CH-8057Zi.irich E-Mail: [email protected] Discovery of Indinavir and Efavirenz, New Therapeutic Agents for AIDS Terry A. Lyle, Merck Research Laboratories, West Point, PA, USA For the treatment of HIV infection, two enzymes are of major interest: The HIV-l Protease (PR) and the Reverse- Tran- scriptase (RT). The HIV -Protease, an aspartic-acid pro- tease active as a dimer, is responsible for H 0 the cleavage of polypeptides assembled at o N~' the cell membrane. The inhibition of the Y I( ; N 1\ 0 = H protease-mediated cleavage of the viral "0 o o o precursor polyproteins results in the pro- duction of noninfectious progeny viral par- ticles. The development of lndinavir start- ed with screening a collection of renin inhibitors. A seven-amino-acid analog 1 1 which contains the hydroxyethylene tran- CONFERENCE REPORTS 296 CHIMIA 1999, 53. No.6 prevents the spread of the virus. Different nucleoside inhibitors like AZT, ddI, ddC, d4T and 3TC are already known, but new QH non-nucleoside inhibitors (NNRTI) are U'O developed to decrease the cytotoxicity and N : to improve the selectivity of the viral polymerases vs.
    [Show full text]
  • Division of Analytical Laboratories
    Michael SWERLOWYCZ 1 Brett FLETCHER 2, Roger JACKSON 2 1 Forensic Toxicology Laboratory, Division of Analytical Laboratories, Sydney, NSW, Australia 2 Drugs & Driving Toxicology Laboratory, Division of Analytical Laboratories, Sydney, NSW, Australia Division of Analytical Laboratories COWS ON COKE Levamisole: A livestock de-wormer in cocaine Introduction Recent DDL specimens (January 2009 onwards) were examined in Levamisole ((S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-B][1,3]thiazole) order to oBtain comparison levamisole data from a range of living has gained attention overseas suBjects. These were mostly cocaine-positive “drug/drive” in recent years as a cutting cases, as well as a numBer of fatal accident, sexual assault and agent for illicit cocaine. murder cases. Interestingly, levamisole appears to Be more common Levamisole, or ( l) -Tetramisole, in samples from living suBjects, But generally at lower concentrations is a drug used in the treatment than the coronial samples. of colon cancer, But primarily it has a veterinary use as an anthelmintic, to PrevalenceofLevamisoleinCocaine-positiveCases(DDL) control parasites in livestock. January2009-June2010 25 70 60 20 50 Levamisole in drug/drive Levamisole around the world and other police 15 40 specimens (DDL). Recently the US Drug Enforcement Administration (DEA) reported a 30 2009 – 2010 10 Percentage(%) significant increase in the prevalence of the drug. In late 2008 the DEA NumberofCases 20 found as much as 30% of illicit cocaine hydrochloride exhiBits contained Mean concentration in 5 levamisole, and By mid-2009 this figure had risen to 70%. This trend has 10 Blood = 0.035mg/L Been seen in other countries around the world and is reflected in illicit 0 0 cocaine exhiBits received By Australian laBoratories.
    [Show full text]
  • Levamisole.Pdf
    8/20/2018 Levamisole | UPMC Hillman Cancer Center Levamisole About This Drug Levamisole is used to treat cancer. This drug is given orally. Possible Side Effects Bone marrow depression. This is a decrease in the number of white blood cells, red blood cells, and platelets. Bone marrow depression usually occurs three to 10 days after the drug is given and may increase your risk of infection, fatigue, and bleeding. Raised, red rash on your arms, legs, back, or chest Abdominal pain or cramping Bitter taste in the mouth Decreased appetite Nausea and vomiting Drowsiness Irritability Sexual problems and reproduction concerns may occur. In men and women both, this drug may temporarily or permanently affect your ability to have children. This cannot be determined before your therapy. In men, this drug may interfere with your ability to make sperm, but it should not change your ability to have sexual relations. In women, menstrual bleeding may become irregular or stop while you are receiving this drug. Do not assume that you cannot become pregnant if you do not have a menstrual period. Women may experience signs of menopause like vaginal dryness or itching. This drug may have harmful effects on the unborn child, so effective methods of birth control should be used during your cancer treatment. genetic counseling is available to you to discuss the effect of this drug therapy on future pregnancies. In addition, a genetic counselor can review the potential risks of problems in the fetus due to this medication if an exposure during pregnancy has occurred. http://hillman.upmc.com/patients/community-support/education/chemotherapy-drugs/levamisole 1/2 8/20/2018 Levamisole | UPMC Hillman Cancer Center Treating Side Effects Ask your doctor or nurse about medication that is available to help you prevent or lessen nausea and vomiting.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Sustiva, INN-Efavirenz
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT SUSTIVA 50 mg hard capsules SUSTIVA 100 mg hard capsules SUSTIVA 200 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION SUSTIVA 50 mg hard capsules Each hard capsule contains 50 mg of efavirenz. Excipient with known effect Each hard capsule contains 28.5 mg of lactose (as monohydrate). SUSTIVA 100 mg hard capsules Each hard capsule contains 100 mg of efavirenz. Excipient with known effect Each hard capsule contains 57.0 mg of lactose (as monohydrate). SUSTIVA 200 mg hard capsules Each hard capsule contains 200 mg of efavirenz. Excipient with known effect Each hard capsule contains 114.0 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule SUSTIVA 50 mg hard capsules Dark yellow and white, printed with "SUSTIVA" on the dark yellow cap and "50 mg" on the white body. SUSTIVA 100 mg hard capsules White, printed with "SUSTIVA" on the body and "100 mg" on the cap. SUSTIVA 200 mg hard capsules Dark yellow, printed with "SUSTIVA" on the body and "200 mg" on the cap. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications SUSTIVA is indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV- 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg. SUSTIVA has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm3, or after failure of protease inhibitor (PI) containing regimens.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Efavirenz) Capsules and Tablets 3 Rx Only
    1 SUSTIVA® 2 (efavirenz) capsules and tablets 3 Rx only 4 DESCRIPTION 5 SUSTIVA® (efavirenz) is a human immunodeficiency virus type 1 (HIV-1) specific, non- 6 nucleoside, reverse transcriptase inhibitor (NNRTI). 7 Capsules: SUSTIVA is available as capsules for oral administration containing either 8 50 mg, 100 mg, or 200 mg of efavirenz and the following inactive ingredients: lactose 9 monohydrate, magnesium stearate, sodium lauryl sulfate, and sodium starch glycolate. 10 The capsule shell contains the following inactive ingredients and dyes: gelatin, sodium 11 lauryl sulfate, titanium dioxide, and/or yellow iron oxide. The capsule shells may also 12 contain silicon dioxide. The capsules are printed with ink containing carmine 40 blue, 13 FD&C Blue No. 2, and titanium dioxide. 14 Tablets: SUSTIVA is available as film-coated tablets for oral administration containing 15 600 mg of efavirenz and the following inactive ingredients: croscarmellose sodium, 16 hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline 17 cellulose, and sodium lauryl sulfate. The film coating contains Opadry® Yellow and 18 Opadry® Clear. The tablets are polished with carnauba wax and printed with purple ink, 19 Opacode® WB. 20 Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- 21 (trifluoromethyl)-2H-3,1-benzoxazin-2-one. 22 Its empirical formula is C14H9ClF3NO2 and its structural formula is: 1 of 45 Approved v2.0 F C 3 Cl O NO 23 H 24 Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. 25 It is practically insoluble in water (<10 µg/mL).
    [Show full text]
  • SUSTIVA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Embryo-Fetal Toxicity: Avoid administration in the first trimester of These highlights do not include all the information needed to use pregnancy as fetal harm may occur. (5.6, 8.1) SUSTIVA safely and effectively. See full prescribing information for • Hepatotoxicity: Monitor liver function tests before and during treatment in SUSTIVA. patients with underlying hepatic disease, including hepatitis B or C SUSTIVA (efavirenz) capsules for oral use coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of SUSTIVA (efavirenz) tablets for oral use hepatic failure, a few occurred in patients with no pre-existing hepatic Initial U.S. Approval: 1998 disease. (5.8, 6.1, 8.6) ---------------------------INDICATIONS AND USAGE---------------------------­ • Rash: Rash usually begins within 1-2 weeks after initiating therapy and SUSTIVA is a non-nucleoside reverse transcriptase inhibitor indicated in resolves within 4 weeks. Discontinue if severe rash develops. (5.7, 6.1, 17) combination with other antiretroviral agents for the treatment of human • Convulsions: Use caution in patients with a history of seizures. (5.9) immunodeficiency virus type 1 infection in adults and in pediatric patients at • Lipids: Total cholesterol and triglyceride elevations. Monitor before least 3 months old and weighing at least 3.5 kg. (1) therapy and periodically thereafter. (5.10) • Immune reconstitution syndrome: May necessitate further evaluation and -----------------------DOSAGE AND ADMINISTRATION----------------------­ treatment. (5.11) • SUSTIVA should be taken orally once daily on an empty stomach, • Redistribution/accumulation of body fat: Observed in patients receiving preferably at bedtime. (2) antiretroviral therapy. (5.12, 17) • Recommended adult dose: 600 mg.
    [Show full text]
  • Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2017 Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations Zachary J. Zimmermann Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Substance Abuse and Addiction Commons Recommended Citation Zimmermann, Zachary J., "Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations" (2017). Dissertations. 3120. https://scholarworks.wmich.edu/dissertations/3120 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE COMBINATIONS by Zachary J. Zimmermann A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2017 Dissertation Committee: Alan Poling, Ph.D., Chair Lisa Baker, Ph.D. David V. Gauvin, Ph.D. Cynthia Pietras, Ph.D. DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE COMBINATIONS Zachary J. Zimmermann, Ph.D. Western Michigan University, 2017 The behavioral and neurochemical effects of cocaine are well established, and it is one of the most widely abused illicit drugs. Illicit cocaine is often adulterated with levamisole, which is an anthelmintic that was withdrawn from the U. S. market in 2000. It has been hypothesized that levamisole, unlike other common adulterants which are added as simple bulking agents, has effects of its own which may be responsible for its use as an adulterant.
    [Show full text]
  • Psychotropic Drugs: Sedatives/Hypnotics, Antidepressants, and Antipsychotics
    PSYCHOTROPIC DRUGS: SEDATIVES/HYPNOTICS, ANTIDEPRESSANTS, AND ANTIPSYCHOTICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir, x NEVIRAPINE Complera, Prezcobix, x RALTEGRAVIR (Viramune) •ABACAVIR (Kivexa, Odefsey, Juluca) Symtuza) (Isentress) Ziagen, Triumeq) xLOPINAVIR (Kaletra) SEDATIVES/HYPNOTICS xLorazepam, oxazepam, temazepam xAlprazolam, Potential for n Potential for p Potential for n bromazepam, benzodiazepine benzodiazepine benzodiazepine buspirone, clonazepam, estazolam, flurazepam, diazepam, nitrazepam, zolpidem, zopiclone xMidazolam, Potential for n Potential for p Potential for n triazolam benzodiazepine benzodiazepine benzodiazepine PSYCHOTROPICS INSTIs NNRTIs PIs RTI xBICTEGRAVIR xELVITEGRAVIR/ x DORAVIRINE x EFAVIRENZ xATAZANAVIR • TENOFOVIR • TENOFOVIR (Biktarvy) COBICISTAT (Pifeltro, (Sustiva, Atripla) (Reyataz/Norvir, ALAFENAMIDE, DISOPROXIL, TDF (Stribild, Genvoya) Delstrigo) Evotaz) TAF (Descovy, (Viread,Truvada, DOLUTEGRAVIR ETRAVIRINE x x Biktarvy, Genvoya, Atripla, Complera, (Tivicay, Triumeq, RILPIVIRINE (Intelence) DARUNAVIR x x Odefsey, Symtuza) Delstrigo, Stribild) Juluca) (Edurant, (Prezista/Norvir,
    [Show full text]
  • Download PDF Flyer
    REVIEWS IN PHARMACEUTICAL & BIOMEDICAL ANALYSIS Editors: Constantinos K. Zacharis and Paraskevas D. Tzanavaras eBooks End User License Agreement Please read this license agreement carefully before using this eBook. Your use of this eBook/chapter constitutes your agreement to the terms and conditions set forth in this License Agreement. Bentham Science Publishers agrees to grant the user of this eBook/chapter, a non-exclusive, nontransferable license to download and use this eBook/chapter under the following terms and conditions: 1. This eBook/chapter may be downloaded and used by one user on one computer. The user may make one back-up copy of this publication to avoid losing it. The user may not give copies of this publication to others, or make it available for others to copy or download. For a multi-user license contact [email protected] 2. All rights reserved: All content in this publication is copyrighted and Bentham Science Publishers own the copyright. You may not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit any of this publication’s content, in any form by any means, in whole or in part, without the prior written permission from Bentham Science Publishers. 3. The user may print one or more copies/pages of this eBook/chapter for their personal use. The user may not print pages from this eBook/chapter or the entire printed eBook/chapter for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained from the publisher for such requirements.
    [Show full text]
  • Prevalence of Levamisole in Urine Toxicology Screens Positive For
    LETTERS portable, handheld ultrasound units are now available. In clinical settings, the marginal benefit of the added diagnos- 1988, Filly,2 in an editorial, called ultrasound the stetho- tic information likely does not justify the added cost of the scope of the future but was concerned about its use in un- device, the time it adds to the physical examination, or the trained hands. In 2002, Dodd3 encouraged teaching the tech- cost of false-positive and incidental findings requiring ad- nique of ultrasound usage to medical students beginning in ditional follow-up. the gross anatomy laboratory and ending in ward rounds We would like to emphasize that the potential for bring- and senior electives. In 2003, Greenbaum4 projected that ing new technology to the physical examination should not in the near future “medical students will also be buying a be viewed as a substitute for developing strong physical ex- ‘sonoscope’” in addition to a stethoscope. He envisioned amination skills. The routine physical examination remains the sonoscope as enhancing the physical examination of all part of standard practice because it is quick, cheap, and readily patients. With the advent of smaller, better-quality, and less- available. It also helps to formulate hypotheses and can al- expensive machines, and medical schools beginning to pro- low a physician to quickly rule in or out competing diag- vide technical training for their students, the use of point- noses. For the most part, the tips and maneuvers that we raised of-care ultrasound is increasing, with applications in physical in our article are simple, inexpensive, and easily mastered.
    [Show full text]